JP Morgan Cazenove retained GlaxoSmithKline PLC (LON:GSK) to Neutral in a report released today.
- Updated: September 15, 2016
Displaying a price of 1,618.75GBX, GlaxoSmithKline PLC (LON:GSK) traded 0.06% higher on the day. With the last stock price up 6.03% relative to the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same period. GlaxoSmithKline PLC has registered a 50-day moving average of 1,662.11GBX and 200-day average of 1,522.63GBX. Trading volume was was down over the average, with 2,100,729 shares of GSK changing hands under the typical 8,900,690 shares.
JP Morgan Cazenove has retained GlaxoSmithKline PLC(LON:GSK) to Neutral in a report released 9/16/2016.
Previously on Thursday September 15 2016, Liberum Capital released a statement on GlaxoSmithKline PLC(LON:GSK) held the target price at 1,900.00GBX. At the time, this indicated a possible upside of 0.18%.
See Graph Below:
A total of 24 brokers have reported on GSK. Three analysts rate the stock a strong buy, six firms rate the stock a buy, 17 firms rate the stock a hold, two firms rate the stock to underperform, and finally 0 brokeragesrate the company as sell with a one year target price of 1,577.33GBX
With a market cap of 0.0 GBX, GlaxoSmithKline PLC has a 52 week low of 1,227.50GBX and a one-year high of 1,716.50GBX with a PE ratio of 2,691.
Brief Synopsis On GlaxoSmithKline PLC (LON:GSK)
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.